Tag: entrepreneurs
-
Genome-Editing Company Raises $94 Million in IPO
3 February 2016. Editas Medicine, developer of treatments for disease that harness editing of the human genome, is raising $94.4 million in its initial public stock offering. The company, trading on the Nasdaq exchange under the symbol EDIT, issued 5.9 million shares priced at $16.00. As of 12 noon on 3 February, the stock is…
-
Electronic Patch Shown to Help Relieve PTSD, Depression
28 January 2016. An electronic device stimulating nerves in the brain was shown in a small clinical study to relieve symptoms associated with post-traumatic stress disorder, or PTSD, and depression. The team developing the patch and taking it to market published results of the study in today’s (28 January) issue of the journal Neuromodulation: Technology…
-
Company Founded to Advance Concussion Treatment
21 January 2016. A San Diego surgeon who conducts research on traumatic brain injury started a new company to take his discovery of a drug for treating concussions to market. The company, Oxeia Biopharmaceuticals founded by Vishal Bansal, began operations today, and revealed its corporate and scientific boards. Bansal studied the connection between metabolic and…
-
BD to Create In-House Health Care Tech Start-Ups
21 January 2016. Medical device maker Becton, Dickinson and Company plans to create new health care technologies on an entrepreneurial model, working with Singularity University in Silicon Valley. Financial aspects of the collaboration were not disclosed. Becton, Dickinson, or BD in Franklin Lakes, New Jersey manufactures medical devices and equipment, as well as diagnostics instruments…
-
Juno Acquires Biotech, Licenses Cell Sequencing Tech
11 January 2016. Juno Therapeutics is gaining single-cell sequencing technology for cancer immunotherapies through the buy-out of biotechnology company AbVitro Inc., and licensing part of that technology to pharmaceutical company Celgene Corp. The AbVitro acquisition is valued at about $125 million, while financial details of the licensing deal with Celgene are not disclosed. Juno Therapeutics,…
-
Clinical Trials to Test Artificial Pancreas
4 January 2016. Two new clinical trials are planned to test a smartphone-based closed-loop artificial pancreas system for people with type 1 diabetes. The system is developed by teams at University of Virginia in Charlottesville and Harvard University, and licensed for commercial development by TypeZero LLC, also in Charlottesville. The trials are funded by a…
-
Start-Up Licenses Founder’s Research for Resistant Bacteria
22 December 2015. A biotechnology company spun-off from University of California in San Diego is licensing technology from the university to develop treatments for bacterial infections now becoming resistant to conventional antibiotics. Financial terms of the licensing agreement between UC-San Diego and Forge Therapeutics were not disclosed. Forge Therapeutics, also in San Diego, is licensing…
-
Airway-on-Chip Model Simulates Asthma, COPD
22 December 2015. A biomedical engineering lab at Harvard University developed a small chip device that acts as a model of human airways to study biological processes and test drugs for diseases such as COPD and asthma. A team from Harvard’s Wyss Institute for Biologically Inspired Engineering describe the device in yesterday’s issue of the…
-
Trial Shows Clot Prevention Drug Safe, Reversible
18 December 2015. An early-stage clinical trial of an experimental drug to prevent blood clots during heart surgery shows the drug prevents platelet accumulation, while still safe and temporary to prevent excess bleeding. The study by a team at Tufts University Medical Center in Boston and Sinai Hospital of Baltimore appears in yesterday’s issue of…
-
Spin-Off Developing Gene Therapies for Blood Disorders
11 December 2015. A new spin-off company from University College London in the U.K. is developing gene therapies to treat hemophilia and related diseases. The company, Freeline Therapeutics, is raising £25 million ($US 38 million) in its first venture funding round. Freeline Therapeutics is founded and commercializing research by UCL hematology professor Amit Nathwani, who…